GlycoMimetics, Inc.

Equities

GLYC

US38000Q1022

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
2.8 USD +9.38% Intraday chart for GlycoMimetics, Inc. +9.38% +18.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GlycoMimetics, Inc. Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1A Healthy Volunteer Study of GMI-1687 CI
GlycoMimetics, Thermo Fisher Unit Set Accord for Manufacturing Uproleselan for Acute Myeloid Leukemia MT
Capital One Initiates GlycoMimetics With Overweight Rating, Price Target is $12 MT
GlycoMimetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : GlycoMimetics, Inc., Q3 2023 Earnings Call, Nov 03, 2023
GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687 CI
Transcript : GlycoMimetics, Inc., Q2 2023 Earnings Call, Aug 02, 2023
GlycoMimetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell 3000E Growth Index CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell Microcap Value Index CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell 3000E Value Index CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell Microcap Growth Index CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell 3000E Index CI
GlycoMimetics, Inc.(NasdaqGM:GLYC) added to Russell Microcap Index CI
GlycoMimetics Says FDA Approves Time-Based Analysis of Overall Survival in Phase 3 Acute Myeloid Leukemia Study MT
GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia CI
GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : GlycoMimetics, Inc., Q1 2023 Earnings Call, May 03, 2023
North American Morning Briefing : Traders Await -2- DJ
Transcript : GlycoMimetics, Inc., Q4 2022 Earnings Call, Mar 29, 2023
North American Morning Briefing : Investor Mood -3- DJ
North American Morning Briefing : Some Calm -2- DJ
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee CI
Insider Sell: Glycomimetics MT
Insider Buy: Glycomimetics MT
Chart GlycoMimetics, Inc.
More charts
GlycoMimetics, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of glycomimetic drugs. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. It is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. The Company is engaged in advancing other preclinical-stage programs, including small-molecule glycomimetic compounds that inhibit the protein galectin-3.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.8 USD
Average target price
7 USD
Spread / Average Target
+150.00%
Consensus
  1. Stock
  2. Equities
  3. Stock GlycoMimetics, Inc. - Nasdaq
  4. News GlycoMimetics, Inc.
  5. GlycoMimetics : Drug Candidate For Acute Myeloid Leukemia Gets Chinese Regulator's Breakthrough Therapy Designation